Objective: Assess perceptions of prevalence, safety, and screening practices for cigarettes and secondhand smoke exposure (SHSe), marijuana (and synthetic marijuana), electronic nicotine delivery systems (ENDS; eg, e-cigarettes), nicotine-replacement therapy (NRT), and smoking-cessation medications during pregnancy, among primary care physicians (PCPs) providing obstetric care.
juana use during pregnancy. [1] [2] [3] These ACOG guidelines were first published in 2002 (revised in 2010), with marijuana added as a committee opinion in 2015. The US Preventive Services Task Force (USPSTF) and American Academy of Family Physicians (AAFP) echo recommendations on cessation of tobacco use during pregnancy (Grade A recommendation). 4, 5 Although the USPSTF concluded that current evidence is insufficient (Grade I) for screening pregnant women for marijuana use and other illicit drugs 6 , others advocate for screening and appropriate referrals in the primary care setting, depending on severity of use. 7 No guidelines exist to screen for electronic-nicotine delivery systems' (ENDS; eg, e-cigarettes) use during pregnancy but the World Health Organization (WHO) recommends cautioning pregnant women against use. 8 These existing guidelines and recommendations make it important to explore how often primary care providers (PCPs) with an obstetric practice may screen for cigarettes and SHSe, marijuana (and synthetic marijuana), and ENDS use during pregnancy. Providers' perceptions of the prevalence and safety of use during pregnancy are likely related to screening behavior and thus important to investigate. Cigarettes, marijuana, and ENDS use fit broadly under an umbrella of substances that are inhalable and known or suspected to cause health risks to developing fetuses. Further, both marijuana and ENDS may be perceived by patients as safe as or less harmful than other substances (eg, cigarettes) and are increasingly available (ie, due to decriminalization/legalization of marijuana), but physicians' perceptions of relative safety for use during pregnancy remain under-researched. Surveying PCPs who teach in academic settings and provide obstetric care may provide an important window into current perceptions of prevalence, safety/ harm, and screening practices for these substances. This group is directly responsible for overseeing trainees' obstetric practices, and therefore their attitudes and behaviors have the potential for significant influence.
Health risks of smoking tobacco 9 and SHSe 10 during pregnancy are well documented, and recent large-scale smoking bans in public places are associated with improved pregnancy outcomes (eg, reduced preterm delivery). 11, 12 It remains unclear, however, how often providers ask pregnant patients about smoking and SHSe or use a gold-standard metric (eg, urine testing for nicotine's metabolite, cotinine), which identifies more pregnant women who smoke than self report alone. 13 SHSe remains a significant public-health burden 10,14 -16 and a recent study found that fewer than half of pregnant women being seen in an urban, university-based prenatal clinic (43%) reported living in a home that completely bans smoking in the home and car(s) 13 , underscoring needs for consistent screening and effective intervention.
Marijuana has recently been decriminalized or legalized in several states, potentially increasing public perception that it has few untoward effects, and it is the most commonly used illicit drug 17 , with recent increases in prevalence 18, 19 (especially with younger adults). 19 Self-reported rates in the past 30 days approached 4% in pregnant women 20 , with some samples (employing urine toxicology) suggesting use as high as 29.6% at the initial prenatal visit. 21 Large, well-controlled studies report significantly increased birth and neonatal risks of marijuana use during pregnancy, including stillbirth (based on data from 663 stillbirth deliveries and 1,932 live-birth deliveries) 22 and low birth weight (LBW), preterm labor, small for gestational age, and admission to a NICU (in a sample of 24,874 women who delivered between 2000 and 2006 in Australia). 23 Another large study (N ϭ 12,000) reported that women using marijuana weekly or more often had babies born 90 g lighter than nonusers. 24 Cannabimimetics and other synthetic compounds (eg, "K2," "Spice"; sometimes marketed as synthetic marijuana) pose potential health risks if used during pregnancy. Although human studies on synthetic drug prevalence among pregnant women and the effects on fetal development are lacking, animal studies have demonstrated the significant potential for neurodevelopmental harm as early as day 16 during human gestation. 25 These data suggest a need for physician education and counseling with pregnant women about poten-tial risks from smoking marijuana (organic or synthetic), but may not fully align with providers' perceptions about safety/risks. A survey of family physicians in Colorado (N ϭ 520) found that most (Ͼ60%) but not all reported that marijuana posed serious physical or mental health risks but this survey did not specifically assess perceptions of risks during pregnancy 26 , making this an open area of investigation.
ENDS (eg, e-cigarettes) operate by heating a liquid-nicotine solution, allowing users to inhale ("vape") the aerosolized solution. These devices have proliferated during the past decade with recent rises in prevalence. 27, 28 Long-term health risks and risks to developing fetuses are largely unknown and poorly characterized, but the WHO recommends cautioning pregnant women about ENDS use 8 , due to preliminary concerns of neurogenic fetal harm. 29 -31 The lack of research on repetitive inhalation of propylene glycol and other additives/ contaminants (present in ENDS vapor) is concerning as well. 29 The early state of ENDS research has not deterred public perception of ENDS having a similar/lower-risk profile than cigarettes, as documented in ENDS users 32 , the general US population 33 , pregnant women 34, 35 , and physicians. 36 Physicians providing care to pregnant women are in a difficult position when patients express interest in using these devices, particularly as smoking cessation aids. Two studies in nonpregnant patients suggest that 30% to 35% of physicians recommend e-cigarettes to their patients as a cessation tool 36, 37 and 67% of physicians felt e-cigarettes were a helpful cessation aid. 36 It is noteworthy that Level I evidence suggests ENDS are not efficacious smoking cessation tools in reproductive-aged women 38, 39 ; and, a recent Cochrane review reported that ENDS as a smoking cessation aid during pregnancy has not been evaluated. 40 The recent Cochrane review also evaluated more widely studied smoking cessation aids and concluded there is borderline evidence that nicotine-replacement therapy (NRT; combined with counseling) may help stop smoking in later pregnancy. 40 However, NRT was no more effective than placebo in well-controlled studies, and insufficient evidence was available to evaluate positive and negative impacts on birth-and infant-related health outcomes (eg, miscarriage and LBW). Some forms of NRT (ie, transdermal patches, inhalers, and spray nicotine products; previously labeled Category D 41 ) have associated risks of fetal harm during pregnancy. 42 In addition, insufficient studies exist to evaluate the safety of bupropion and varenicline during pregnancy and no clinical guidelines recommend them in pregnancy. 40 Physicians are likely to weigh the risks of continued smoking during pregnancy against the risks of ENDS, NRT, and smoking-cessation medications, but the literature lacks reports on physicians' safety perceptions and prescription practices for ENDS, NRT, and smoking-cessation medication use during pregnancy. Obstetric care providers are well positioned to screen for cigarette use, SHSe, and marijuana, synthetic marijuana (eg, "Spice"), and ENDS use during pregnancy, which is a critical first step before referrals or interventions targeting cessation can occur. Evidence supports that smoking cessation interventions during pregnancy can be effective (eg, NRT increases cessation by 40% in late pregnancy) but more work is needed for larger effects. 40, 43 Further, evidence-based interventions with nonpregnant populations for SHSe 44 and marijuana 45 have not been tested with pregnant patients, and a recent Cochrane review concluded that across 14 studies of psychosocial interventions for drug use with pregnant women, there was no difference in treatment outcomes. 46 It is clear that efficacious interventions to reduce use and exposure to the substances discussed herein are sorely needed but many physicians may feel compelled to screen for and make recommendations to avoid cigarettes, SHSe, marijuana and synthetic marijuana, and ENDS, rather than wait for well-supported empirical treatments for these substances. For example, the 5 A's (ask, advise, assess [readiness], assist, and arrange [followup]) for smoking cessation. 47 The overarching objective of this investigation was to assess and describe perceptions of prevalence and safety/risk and current screening practices related to cigarettes, SHSe, marijuana and synthetic marijuana, ENDS, NRT, and smoking-cessation medications during pregnancy among PCPs providing obstetric care within academic settings. We hypothesized that obstetric care providers would perceive these exposures as unsafe but screening would not be universal. These data may facilitate recommendations for improved care to pregnant patients.
Materials and Methods

Ethical Review
The Committee for the Protection of Human Subjects at UTHealth and the IRB at Baylor College of Medicine (BCM) approved a pilot survey and methodology. The final design was approved by the AAFP IRB (16 -255) . Participants gave informed consent. 48, 49 Four e-mail reminders were sent. Some e-mails were undeliverable (n ϭ 80) and some providers opted out (n ϭ 68).
Participants and Procedures
The survey (open from February 2 to March 20, 2016) contained 56 questions spanning 5 separate research proposals. Given that our focus was on obstetric practice, we only included physicians who responded affirmatively to, "Do you currently provide labor and delivery maternity care within the United States?" (see Appendix). Skip logic prevented survey participants who did not provide labor and delivery care from answering our group's survey contributions, reducing burden for participants with less-frequent or no contact with pregnant patients.
Survey Instrument
We surveyed the literature, developed and piloted survey items locally, and solicited feedback from OB/GYN and PCP colleagues to develop, adapt, and refine our question set for parsimony and coherence. Our final question set (see Appendix) was reduced to accommodate multiple assessment domains in the CERA survey, given that topic areas are generally limited to 10 questions 48 and underwent additional piloting by CERA leadership. 49 Question 1 assessed the inclusion criterion and question 2 was included to characterize the number of patients under the age of 18 years seen in a practice.
Question 3 asked providers to estimate the prevalence of use for each substance during pregnancy (from their own clinic). Response options for prevalence questions were developed/refined to correspond closely to available data during pregnancy. "Very few (1% to 5%)" was selected for synthetic marijuana and smoking-cessation medication use, estimated to be infrequent events by our team (published data are lacking). "Some (6% to 25%)" was chosen to correspond with the reported prevalence range for smoking 3 months before pregnancy (23.0%) and past 3 months of pregnancy (12.8%) 50 , and marijuana use during pregnancy 4% to 30%. 20, 21 "Many (26% to 50%)" was provided to accommodate physicians working with populations using substances to a greater degree. "None (0%)" and "Most (Ͼ50%)" completed the response range.
For question 4, respondents indicated how safe it is for pregnant women to use each substance, be exposed to secondhand smoke, or breastfeed while smoking (after delivery) using a 5-point scale ("Very Safe, Safe, Somewhat Safe, Unsafe," or "Very Unsafe").
Providers indicated how often they screen pregnant patients (question 5) on a 6-point scale ("Never, Rarely, Sometimes, Often, Very Often," or "Always"). Further, we asked about several methods for tobacco/nicotine and marijuana screening (ie, patient report and laboratory testing) in question 6. Question 7 surveyed ENDS, NRT, and smoking cessation prescription practices.
We adapted 2 questions about ENDS safety reported in peer-reviewed publications. 36 Specifically, to assess whether providers perceived e-cigarettes to have a lower cancer risk than traditional cigarettes, we added "About the same" as a response option, along with "Yes" and "No" (question 8). Question 9 assessed how often providers were asked by patients about the safety of e-cigarette use or their efficacy as a smoking cessation aid (content was adapted to assess "pregnant patients" and "all other patients" separately). Question 10 queried whether providers would advise patients not to use marijuana (if it is or becomes legal in their state).
Statistical Analyses
The primary data analytic aims were to describe the areas surveyed via frequency counts. The response rate was conservatively estimated as the quotient of all responders (partial and complete) divided by all intended recipients (N ϭ 3750). 51 Categorical data were compared using 2 tests for equal proportions and all comparisons were evaluated at the 0.05 significance level (in SAS 9.4, SAS Institute Inc., Cary, NC). We collapsed some directly adjacent response options due to low endorsement (ie, Ͻ5 responses/category; see relevant Table notes) .
Results
Response Rate and Characteristics of Family Physicians Providing Obstetric Care
The response rate was 33.3% (N ϭ 1248) of the 3750 intended survey recipients, inclusive of providers with and without a current obstetric practice. A majority (90.6%; n ϭ 1131 of 1248) responded to the eligibility question and 417 (36.9%; of 1131) reported providing labor and delivery obstetric care. Obstetric care providers tended to be female (56.0%) and white, non-Hispanic (80.3%). Table 1 contains other provider characteristics and demonstrates numerous statistically significant differences in characteristics across providers with and without a current obstetric practice (eg, a greater proportion of the sample with a current obstetric practice tended to be female compared with nonobstetric providers; 56.0% vs 46.6%; P Ͻ .01). The final sample size for subsequent data comprised the 417 family medicine physicians who reported providing labor and delivery maternity care.
Perceived Prevalence
Providers most commonly reported that "some (6% to 25%)" of their pregnant patients used cigarettes and marijuana (see Table 2 and Figure 1A ). Fewer providers selected "Some (6% to 25%)" for ENDS/e-cigarette use while pregnant, with "Very Few (1% to 5%)" chosen more frequently. Perceived NRT usage while pregnant was similar to providers' endorsements for e-cigarettes. Nearly 3 quarters of the sample selected that smoking-cessation medications (bupropion and varenicline) were likely used by "None (0%)" or "Very Few (1% to 5%)" of pregnant women. Slightly more than a third of providers (37%) selected "Very few (1% to 5%)" or "None (0%)" for the prevalence of synthetic marijuana during pregnancy. However, provider uncertainty was common for synthetic marijuana (57% selected "Do not Know") and ENDS (27% chose "Do not Know"). Slightly fewer providers selected "Do not Know" for NRT (17%) and smoking-cessation medications (17%).
Perceived Safety of Use during Pregnancy
Over 90% of providers tended to perceive that most substances/exposures assessed were generally unsafe while pregnant, with the exception of NRT. Over half (56%) of providers endorsed that NRT was safe to use during pregnancy (see Table 3 ). Further, a minority (27%) indicated that breastfeeding while smoking was safe.
The largest proportion of providers felt ENDS/ e-cigarettes have a lower cancer risk compared with traditional cigarettes (45.1%; n ϭ 176) with the remainder relatively evenly split between the two having the same level of risk (28.0%; n ϭ 109) or not having a lower risk (26.9%; n ϭ 105).
Screening Practices
Survey participants reported screening consistently (according to "Always" endorsements) for cigarette use (85%) and marijuana use (63%), with fewer than half of the sample screening for e-cigarettes/ ENDS (33%) or synthetic marijuana (28%) consistently (see Table 4 and Figure 1B) . Further, 48% reported screening consistently for SHSe in the home. Overall, fewer than a quarter (17.7%) of providers reported consistently screening for all 4 substances and SHSe. Nearly all providers (99.5%; n ϭ 388) reported using a patient-completed form or interview to screen for tobacco/nicotine use, with slightly fewer (95.6%; n ϭ 373) reporting this same method for screening for marijuana. A third of providers (31.5%; n ϭ 123) reported using laboratory screening for marijuana and very few providers reported using laboratory testing for tobacco/nicotine use (2.8%; n ϭ 11).
Prescriptions/Recommendations for Smoking Cessation during Pregnancy
A majority of providers have recommended NRT (68.4%; n ϭ 267) to pregnant smokers who want to quit, with a third prescribing/recommending bupropion (30.8%; n ϭ 120), 6.7% (n ϭ 26) recom- mending/prescribing varenicline, and 4.4% (n ϭ 17) prescribing/recommending e-cigarettes to quit. A quarter (24.4%; n ϭ 95) reported that they have not prescribed nor recommended any of these as smoking cessation aids to pregnant women.
Patient Interest in ENDS and Recommendations on Recreational Marijuana
Providers most frequently indicated they are "never" (36.1%; n ϭ 140) or "rarely" (42.3%; n ϭ 164) questioned by pregnant patients about ENDS safety or smoking cessation efficacy. Regarding all other (nonpregnant) patients, physicians tended to report greater patient interest, by reporting "sometimes" (46.8%; n ϭ 182) or "frequently" (13.4%; n ϭ 52) being asked about e-cigarettes/ENDS. Most providers reported they would recommend pregnant patients not use recreational marijuana (if it became legal or already is) in the providers' states (97.2%; n ϭ 381) but fewer reported this for nonpregnant patients (70.4%; n ϭ 276).
Discussion
This study with family physicians who practice in academic settings and provide obstetric care explored perceptions of prevalence, safety/risk, and current screening practices during pregnancy related to several inhalable substances (cigarettes, Where numbers do not add up to the total sample size, the remainder represent missing data. *The categories, "Ͻ30" and "30 to 39" were combined to "Ͻ40" due to fewer than 5 respondents in the Ͻ30 age range. † "Visiting professor" and "Not applicable (N/A)" were combined due to fewer than 5 respondents endorsing visiting professorships. ‡ Only 1 respondent chose "other". §" Non-academic physician" and "other" were combined due to fewer than 5 respondents endorsing "non-academic physician." The stem for this question was, "Do you OR any of your family physician practice partners provide the following services?" PCP, primary care physicians; SD, Standard Deviation. Where numbers do not add up to 417, the remainder represent missing data. *The response categories of "Many (26% to 50%)" and "Most (Ͼ50%)" were collapsed due to low endorsement (n Ͻ 5) of the "Most (Ͼ50%)" category for all survey items. † "How many of your pregnant patients are Ͻ18 years of age?" ‡ The full stem was, "In your practice, please estimate how many pregnant patients use the following:" § The full stem was, "Synthetic marijuana (e.g., K2, Spice)." The full stem was, "Nicotine replacement therapy (e.g., patches, gum, lozenges, nasal spray, or inhaler)." ¶ The full stem was, "Medication for smoking cessation (Bupropion ͓Zyban͔ or Varenicline͓Chantix͔)." ENDS, electronic nicotine delivery systems; NRT, nicotine-replacement therapy.
SHSe, marijuana, synthetic marijuana, and ENDS), as well as NRT and smoking-cessation medications. Over a third of family physicians in academic settings reported providing labor and delivery services and this large population has significant responsibility for educating future physicians on appropriate screening practices with pregnant patients. Indeed, these providers' perceptions of prevalence and safety/risk, and recommendations to patients regarding cigarettes (and SHSe), marijuana (and synthetic marijuana), ENDS, NRT, and smoking-cessation medications are likely to shape the screening practices of numerous trainees. Many of these providers perceived a significant proportion of pregnant women were using cigarettes, marijuana, and ENDS, consistent with prevalence estimates. 19, 20, 50 These data also illustrated that many providers are also uncertain about the extent of synthetic marijuana use and to a lesser extent ENDS, among pregnant women under their care.
Further, an overwhelming majority reported that all substance use/exposure surveyed was unsafe, with a slight majority (56%) reporting that NRT use during pregnancy was safe.
Many providers reported consistent screening for cigarette use during pregnancy (85%), in compliance with ACOG's, AAFP's, and USPSTF's guidelines. This trend did not fully extend to SHSe during pregnancy, as 52% reported some SHSe screening inconsistency. Nearly two thirds (63%) reported consistent screening for marijuana (recommended by ACOG), and 33% and 28% reported consistent screening for ENDS and synthetic marijuana, respectively, even in the absence of an existing guideline to do so. Nearly 1 in 5 providers (18%) reported screening consistently for all substances surveyed (including synthetic marijuana and SHSe), in line with our a priori predictions, demonstrating opportunity for increased screening during pregnancy. The overwhelming majority relied on patient report for screening, with a third using laboratory testing for marijuana and fewer than 3% testing for nicotine's major metabolite (cotinine) via urine screening. Use of a multiple-choice question for cigarette screening is valid and recommended 52 and objective measures may further improve identification. 13 Conversely, overreliance on self report may miss a quarter (23%) of women using marijuana at their first prenatal visit. 21 Universal laboratory screening is expensive, however, and likely contributes to its underutilization. Further, physicians may be reluctant to address substance use given legal mandates (varying across states) that may affect patient custody and may lack resources for assisting disadvantaged women.
Similar to others 36 , almost half of our sample felt that ENDS/e-cigarettes carry less risk for cancer than traditional cigarettes. Further, survey respondents indicated that patients have expressed interest in ENDS' safety and efficacy for smoking cessation, though less so for pregnant women. Accordingly, our sample reported low levels (Ͻ5%) of recommending e-cigarettes/ENDS as smoking cessation aids during pregnancy. Surprisingly, over half of the sample felt that NRT use by pregnant women was at least "somewhat safe" despite evidence of fetal risks. 42 Further, a sizable proportion reported prescribing bupropion and varenicline (with human studies currently lacking) for use during pregnancy. The majority (73%) perceived breastfeeding while smoking as unsafe, although minimal data supports risks to the infant from breastfeeding while the mother remains a smoker. 53, 54 This survey item may need refinement, however, to delineate risks (56) 171 (44) Breastfeed while smoking 103 (27) 283 (73) Where numbers do not add up to 417, the remainder represent missing data. *The question stem was, "In your personal opinion, how safe is it for pregnant patients (during ANY trimester) to:". † Response options included, "Very Safe, Safe, Somewhat Safe, Unsafe, or Very Unsafe." Very safe, safe, and somewhat safe were collapsed to "Safe," and unsafe and very unsafe were collapsed to "Unsafe," for parsimony and due to low endorsement for some categories. ENDS, electronic nicotine delivery systems; NRT, nicotinereplacement therapy (eg, patches, gum, lozenges, nasal spray, or inhaler); SHS, secondhand smoke. (1) 5 (1) 24 (6) 27 (7) 328 (85) Presence of a smoker in home ‡ 10 (3) 31 (8) 54 (14) 107 (28) 184 (48) Use of marijuana 5 (1) 38 (10) 45 (12) 56 (15) 241 (63) Use of synthetic marijuana 133 (37) 63 (16) 38 (10) 34 (9) 108 (28) Use of e-cigarettes/ENDS 81 (21) 68 (18) 52 (13) 59 (15) 127 (33) Where numbers do not add up to 417, the remainder represent missing data. *"Never" and "rarely" were collapsed due to low response endorsement (nϽ5) for several survey items, including cigarettes, presence of a smoker, and marijuana. † The full stem was, "In your practice, how often do you screen your pregnant patients (via ANY method: interview, patient-completed form, or laboratory testing) for the following:" ‡ The full stem was, "Presence of a smoker (other than the pregnant patient) in the home." ENDS, electronic nicotine delivery system; SHS, secondhand smoke.
from tobacco constituents transmitted through breast milk contrasted with SHSe risks from the mother.
The relatively high degree of consistent screening during pregnancy for cigarette use is encouraging but room for improvement exists for SHSe screening, given the well-established risks. 9, 10, 12 Trends for marijuana screening were positive as well, given emerging health risks. [22] [23] [24] Providers screening for or aware of synthetic marijuana use should recommend cessation, given high potential for harm. 25 Providers are likely to increasingly face questions about ENDS with rising prevalence in younger adults 27 ; and, e-cigarette use surpassed traditional cigarette use in 2011 to 2015 among high school students, as cigarette use has declined in this group. 55 Although no guidelines currently exist for ENDS, the potential for neurodevelopmental harm is present. The lack of clear guidelines will undoubtedly pose challenges for providers who recommend cessation of all cigarette/ENDS use and exposure but may consider the use of ENDS, NRT, or smoking-cessation medications for patients unable to quit cigarettes without assistance.
Ideally an evidence-based intervention (or referral) would dovetail with screening to reduce use and exposure across the substances surveyed. As reviewed in the Introduction, however, many of these substances lack empirically supported interventions or treatments to reduce use, and smoking cessation treatments during pregnancy have relatively modest effects. The relative lack of empirically supported treatments could influence providers' willingness to screen for these substances, even though fewer than 10% of providers felt it was safe for patients to use these substances while pregnant. There is clearly an urgent need for more research to identify effective interventions for women using these substances during pregnancy.
These data represent a comprehensive assessment of family physicians in academic settings, who practice labor and delivery obstetric care, regarding screening for smoking, SHSe, marijuana, and other substances but our study was not without limitations. No data were available on nonresponders, precluding evaluations of sampling bias. Further, inclusion criteria limited our sample to physicians providing obstetric care and these results may not generalize to physicians who provide prenatal care or have contact with pregnant patients during other primary care visits. By sampling physicians who provide obstetric care, however, we assessed those with the greatest contact and in a position to deliver health-related messages to pregnant women. These self-reported, cross-sectional data should be interpreted with caution. Perceptions of prevalence and screening practices were not compared against objective data, such as health-record documentation of providers' screening. In addition, physician attitudes may change, as new data on marijuana, synthetics, and ENDS emerge and related legal decisions are continually issued (eg, US Food and Drug Administration regulation of e-cigarettes as tobacco products 56 ).
Conclusions
This assessment of PCPs in academic settings, who provide obstetric care, demonstrated that these providers perceive women are using the surveyed substances during pregnancy and that this use is unsafe. These data offer insight to the broader population of obstetric providers' screening practices for commonly used inhalable substances. Indeed, nearly all survey participants are teaching future generations of PCPs to provide obstetric care, and responses highlight the opportunity for increased screening during pregnancy. Screening barriers in combination with the implementation of intervention/treatment should be explored in follow-on work. At a minimum, all pregnant patients could be asked about their use of these substances, as a starting point to both discover and mitigate potential harm. Existing evidence suggests recommendations to terminate use are appropriate. At present, it suffices to say that no amount of nicotine nor marijuana nor synthetic drug exposure is known to be safe in pregnancy and the risks of potential harm have not been fully evaluated. 
Instructions:
The following questions relate to the prevalence of tobacco products (including electronic-cigarette ͓e-cigs͔ and other electronic-nicotine devices ͓ENDS͔) and marijuana (including synthetic marijuana use) during pregnancy. An e-cigarette is a device that emits doses of vaporized nicotine to be inhaled. Synthetic marijuana refers to "Spice" or "K2," or any other substance sold over-the-counter (often in gas stations) and commonly marketed or perceived as a synthetic cannabinoid. 
